Trending...
- RockNTix takes on the ticketing monopoly with a view to abolishing service fees - 164
- Country Artist Ashley Wineland to Release Poignant Ballad 'I'm Going Home'; Announces Her 2023 National Tour
- San Jose: : San José's Chief Building Official Chu Chang Honored as California Building Official of the Year
HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023. Since its founding, Avirmax Biopharma Inc (ABI) has been focusing on developing an effective gene therapy product, ABI-902 for glaucoma treatment. Intravitreal administration of ABI-902 has demonstrated retinal ganglion cell (RGC) protection against N-methyl-D-Asparate (NMDA) excitotoxicity in mice and rats of partial optic nerve transection (pONT) measured by Detection of Apoptosing Retinal Cell (DARC) imaging technology. ABI-902 is manufactured by Avirmax CMC Inc.
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
- Murder on the Links WORLD PREMIERE at North Coast Repertory Theatre
- Ferocious Talent Management Europe Celebrates the Fifth Grammy Win For Our Very Own Rob Chiarelli At
- Majority Of Medicare Advantage Plans Offer Added Benefits
- California: Governor Newsom Announces Appointments 3.24.23
- California Continues Creating Jobs
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Filed Under: Business
0 Comments
Latest on The Californer
- Alten Construction and Channel Lumber donate $2,500 worth of lumber to Redwood High School
- Plan for 50 affordable apartments on Bryant coming soon
- Keebos Unveils Keebos 2.0: The Ultimate Crossbody Phone Case
- Groundbreaking DUC indie record label announces pro-union anthem for downtrodden workers everywhere
- Honda Campus All-Star Challenge Returns to In-Person Competition in Longstanding Celebration of HBCU Academic Excellence
- Shelter Structures America Debuts Everun America at Con Expo
- ArtisTech Media and Creative Commons Announce a New Trademark Agreement for ccMixter
- 100+ Award Winning "Sweetest Vacation" Solicits Filmocracy Film Market Major Public Distribution
- Tupperware Brands Corporation (TUP) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Tupperware Brands Corporation
- Protecting and enhancing wildlife populations could be a global warming game changer
- Cummings Graduate Institute Celebrates New DBH Graduates
- Water Damage Repair Services, Basement Floods, Sewage Removal Company - Hesperia, CA
- Deol Data Strategically Appoints Ravi Singh to Its Advisory Board
- Top 6 AGS Highlights at the Indian Gaming Trade Show
- Hai Robotics Wins Innovation Award for Existing Product at Promat 2023
- 2023 National Farmworker Awareness Week
- Orbex Introduces Double Profits for New Traders
- Against All Odds: University of California Berkeley Men's Cricket Team Lifts NCCA Cup
- Tech N9ne Surprises Kxng Crooked Interview with I Only Touch Greatness
- Quotehunt.co.uk: Revolutionising the UK B2B Market with Comprehensive Comparison Services for Small Businesses